A systematic literature review to examine the considerations around pregnancy in women of child-bearing age with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) or aquaporin 4 neuromyelitis optica spectrum disorder (AQP4+ NMOSD)

Leite, Maria Isabel; Panahloo, Zoya; Harrison, Niall; Palace, Jacqueline

doi:10.1016/j.msard.2023.104760

Cited by 5 publications

(2 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since MOGAD can affect women of childbearing age, it is crucial to comprehend the disease’s effects on pregnancy and the postpartum period, as this can greatly influence family planning decisions. Although data is limited, a systematic literature review concluded that disease activity appears to be attenuated during pregnancy in MOGAD patients, with an increased risk of relapse during the postpartum months [ 75 ].…”

Section: Mogad and Pregnancymentioning

confidence: 99%

Myelin Oligodendrocyte Glycoprotein-Antibody Associated Disease: An Updated Review of the Clinical Spectrum, Pathogenetic Mechanisms and Therapeutic Management

Gklinos,

Dobson

2024

Antibodies

View full text Add to dashboard Cite

Clinical syndromes associated with antibodies against myelin oligodendrocyte glycoprotein (MOG) are now recognized as a distinct neurological disease entity, and are gaining increasing attention. The pathogenic mechanisms underlying MOG-antibody disease (MOGAD) remain incompletely understood. Case series, facilitated by registries, and observational studies over the past few years have shed increasing light on the clinical aspects and therapeutic approaches of MOGAD. MOGAD may manifest with a variety of clinical syndromes, including acute disseminated encephalomyelitis (ADEM), autoimmune encephalitis, optic neuritis (ON) and transverse myelitis (TM). MOGAD can be either monophasic or relapsing. This review aims to provide a comprehensive updated description of the clinical spectrum, paraclinical features, and prognosis of MOG-antibody disease, as well as summarize its therapeutic considerations. Randomized clinical trials, standardized diagnostic criteria and treatment guidelines are the steps forward.

show abstract

Section: Mogad and Pregnancymentioning

confidence: 99%

Myelin Oligodendrocyte Glycoprotein-Antibody Associated Disease: An Updated Review of the Clinical Spectrum, Pathogenetic Mechanisms and Therapeutic Management

Gklinos,

Dobson

2024

Antibodies

View full text Add to dashboard Cite

show abstract

“…For a full review of available treatment options for AQP4-NMOSD and MOGAD, treatment dosing, treatment-related side effects, and treatment during pregnancy, refer to the article "Therapeutic Approach to Autoimmune Neurologic Disorders" by Stacey L. Clardy, MD, PhD, FAAN and Tammy L. Smith, MD, PhD, 82 in this issue of Continuum, in addition to dedicated articles on this topic. 3,11,[83][84][85][86] Four types of drugs have been proven effective for relapse prevention in AQP4-NMOSD by randomized clinical trials: rituximab (anti-CD20), 87 inebilizumab (anti-CD19), 88 satralizumab and tocilizumab (anti-IL-6), [89][90][91] and eculizumab and ravulizumab (anti-C5). 92,93 Of these treatments, satralizumab, inebilizumab, and eculizumab are currently US Food and Drug Administration (FDA) approved in the United States (CASE .…”

Section: Treatment Of Acute Attacksmentioning

confidence: 99%

NMOSD and MOGAD

Sechi

2024

CONTINUUM: Lifelong Learning in Neurology

View full text Add to dashboard Cite

OBJECTIVE This article reviews the clinical features, MRI characteristics, diagnosis, and treatment of aquaporin-4 antibody–positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) and myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD). The main differences between these disorders and multiple sclerosis (MS), the most common demyelinating disease of the central nervous system (CNS), are also highlighted. LATEST DEVELOPMENTS The past 20 years have seen important advances in understanding rare demyelinating CNS disorders associated with AQP4 IgG and myelin oligodendrocyte glycoprotein (MOG) IgG. The rapidly expanding repertoire of immunosuppressive agents approved for the treatment of AQP4-NMOSD and emerging as potentially beneficial in MOGAD mandates prompt recognition of these diseases. Most of the recent literature has focused on the identification of clinical and MRI features that help distinguish these diseases from each other and MS, simultaneously highlighting major diagnostic pitfalls that may lead to misdiagnosis. An awareness of the limitations of currently available assays for AQP4 IgG and MOG IgG detection is fundamental for identifying rare false antibody positivity and avoiding inappropriate treatments. For this purpose, diagnostic criteria have been created to help the clinician interpret antibody testing results and recognize the clinical and MRI phenotypes associated with AQP4-NMOSD and MOGAD. ESSENTIAL POINTS An awareness of the specific clinical and MRI features associated with AQP4-NMOSD and MOGAD and the limitations of currently available antibody testing assays is crucial for a correct diagnosis and differentiation from MS. The growing availability of effective treatment options will lead to personalized therapies and improved outcomes.

show abstract

Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease

Palace,

Fadda

2024

Reference Module in Neuroscience and Biobehavioral Psychology

View full text Add to dashboard Cite

A systematic literature review to examine the considerations around pregnancy in women of child-bearing age with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) or aquaporin 4 neuromyelitis optica spectrum disorder (AQP4+ NMOSD)

Cited by 5 publications

References 67 publications

Myelin Oligodendrocyte Glycoprotein-Antibody Associated Disease: An Updated Review of the Clinical Spectrum, Pathogenetic Mechanisms and Therapeutic Management

Myelin Oligodendrocyte Glycoprotein-Antibody Associated Disease: An Updated Review of the Clinical Spectrum, Pathogenetic Mechanisms and Therapeutic Management

NMOSD and MOGAD

Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease

Contact Info

Product

Resources

About